Analysis of the status quo of oral sugar-reducing drugs in China: local enterprises to copy-based foreign-led innovative drugs

Diabetes is a group of metabolic diseases characterized by high blood sugar, which is the only criterion for diagnosing diabetesAccording to the latest data from the 9th edition of the Global Diabetes Survey released by the International Diabetes Alliance, there were about 463 million people with diabetes worldwide between the ages of 20 and 79 in 2019, including 116.4 million in China, India and the United States, with 116.4 million and 077.031 million, respectivelyHalf of existing adult diabeticpatients do not know they are sick, so they are at high risk of severe diabetes-related complicationsChina and the United States spend $294.6 billion and $109 billion on diabetes-related health, respectively, compared with about 834,000 people die each year from diabetes in ChinaAs a result, blood sugar control minimizes complications that extend life and socially related expensesoral sugar-lowering drugs can be divided into six main categories by mechanism of action, insulin-promoting agents, diazebutts, alpha-glucosinase inhibitors, insulin-allergens, DPP-4 enzyme inhibitors and SGLT2 inhibitors1Insulin pronouns: sulfonya-type pronouns are insulin-reducing by stimulating islet beta cells, and are suitable for mild and moderate type 2 diabetes, especially those with low insulin secretion function, including Grebenquine, Grecit, Grecit, Grequinone, Gremetina, etc.; Products mainly include Reglinay, Nagrenay2Dicosytino: the sugar reduction mechanism is to increase the anaerobic enzyme solution of sugar, improve the surrounding tissue resistance to insulin, inhibit the absorption of sugar in the intestines and liver sugar production, suitable for type 2 diabetes patients, especially obese patients with insulin resistance or insulin haemorrhoids of the preferred sugar-lowering drug, the main product is metformin4Insulin allergen: pyrethroidddrexant derivatives allergen, the sugar reduction mechanism is by increasing the sensitivity of tissue cells to insulin, strengthen the surrounding tissue intake and use of sugar, reduce the production of liver sugar, especially suitable for insulin resistance-based type 2 glycuria patients, the main products are roglitazone and ketone5.DPP-4 enzyme inhibitors: dipeptide-based peptide enzyme 4 inhibitors, can inhibit the inactivation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin secretion polypeptides (GIP), improve endogenous GLP-1 and GIP levels, promote the release of insulin by islet beta cells, while inhibiting islet alpha cells to secrete glucagon, improve insulin levels, lower blood sugar levels, and induce low blood sugarProducts include Sigretin, Vigretin, Sagretin, Agretin, Ligletin, Gigletin and Sigretin6.SGLT-2 inhibitors: sodium-glucose co-transport protein 2 inhibitors, is a new class of anti-diabetic drugsBy inhibiting the reabsorption of glucose by the kidneys, excess glucose is excreted from the urine, lowering blood sugarProducts mainly include Dalgley Net, Engli net, Cagle net, Igli net, Rugli net, Togre net from the global market, DPP-4 and SGLT-2 inhibitors have gradually become the main drug use, due to different stages of development, China's oral sugar-lowering drug market and foreign countries have a clear difference About 70% of the market is occupied by foreign companies such as Novo Nordisk, Bayer, Sanofi, Squibb, Lilly, Novartis and others According to PDB sample hospital data, in 2017 China's oral sugar-reducing drugs in the top three nameapo sugar, metformin, gremetain market share of 33.8%, 17.7%, 9.3% In the case of Acapo Sugar, since its listing in China in 1995, only Bayer, a former pharmaceutical company, has been in the market until the patent expires, and the generic drugs of East China Pharma and Green Leaf Pharmaceuticals were listed in 2015, with Bayer accounting for 68.75 percent of the market share in China in 2017 and 29.02 percent in East China Pharmaceuticals because diabetes diagnosis and treatment is very professional, and drug use, and most cases need to be combined, so doctors for patients after the use of drugs play a decisive role, pharmaceutical companies in the marketing needs to increase the intensity of academic promotion Chinese local enterprises to produce generic drugs mainly, enterprises are more competitive, to the dpp-4 inhibitors will expire, for example, Vigretin, Sagretin and Sigretin will expire in 2019 and 2021, respectively, according to PDB sample hospital data, but in 2017 sample hospital sales have reached 280 million yuan, accounting for 8.6% of the market share of oral anti-sugar drugs, of which Sigretin and Sigretin in the leading position At present, local enterprises began to compete for imitation, the current application of sigletin manufacturers mainly include, Chen Xin Pharmaceuticals, Gan Li Pharmaceuticals, Dongsun Pharmaceuticals, Zhengdaya Qing, Yangzijiang Pharmaceuticals, Tonghua Dongbao, Stone Pharmaceuticals and Collen, the competition is extremely fierce since the implementation of the national centralized procurement of drugs, the mechanism to price-for-value is effective, the traditional drug price reduction space is large, to Acapo sugar as an example, the second batch of state-organized drug centralized procurement, Bayer quoted 5.42 yuan, a decline of nearly 90% Local companies need to continuously improve their research and development capabilities to develop new drugs in order to compete in the future and even in the national procurement of a position.